Financial Performance - The unaudited revenue of RMH Holdings Limited for the six months ended June 30, 2022, was approximately S$7,713,000, representing an increase of approximately S$3,090,000 or 66.8% compared to S$4,623,000 for the same period in 2021[9]. - The unaudited loss for the Group was approximately S$4,948,000 for the six months ended June 30, 2022, an increase of approximately S$2,119,000 or 74.9% compared to a loss of S$2,829,000 for the same period in 2021[10]. - The total comprehensive loss for the period was S$5,048,000, compared to S$2,885,000 for the same period in 2021[14]. - The company reported a loss before taxation of S$4,948,000 for the six months ended June 30, 2022, compared to a loss of S$2,791,000 in the same period of 2021[24]. - Total comprehensive loss for the period was S$5,046,000, compared to S$4,947,000 in the previous year[21]. - Loss attributable to the owners of the Company for the six months ended 30 June 2022 was S$4,948,000, compared to S$2,829,000 for the same period in 2021, representing an increase of 74.8%[109]. - Loss per share was 0.44 Singapore cents for the six months ended June 30, 2022, compared to 0.40 Singapore cents for the same period in 2021[11]. Revenue Breakdown - Revenue from healthcare services amounted to S$5,481,000, up 17.6% from S$4,661,000 in 2021[91]. - Trading sales significantly increased to S$1,946,000 from S$157,000, marking a substantial growth[91]. - Revenue recognized at a point in time was S$4,602,000, compared to S$2,179,000, reflecting a 111.0% increase[87]. - Other services, primarily related to laboratory tests, generated S$862,000, an increase of 20.1% from S$718,000[87]. - The Group's healthcare services revenue breakdown includes S$506,000 from Aesthetic Services, S$1,116,000 from Consultation Services, S$1,793,000 from Prescription and Dispensing Services, and S$1,489,000 from Treatment Services[186]. - Revenue from Aesthetic Services was S$506,000 for the six months ended 30 June 2022, attributed to increased capacity following the easing of COVID-19 measures and new dermatologists joining[188]. - Consultation Services revenue increased by approximately S$170,000, from S$946,000 in the six months ended June 30, 2021 to approximately S$1,116,000 in the same period of 2022[188]. - Revenue from Prescription and Dispensing Services rose by approximately S$387,000, from S$1,406,000 for the six months ended June 30, 2021 to approximately S$1,793,000 for the same period in 2022[188]. - Treatment Services revenue increased by approximately S$222,000, from S$1,267,000 in the six months ended June 30, 2021 to approximately S$1,489,000 in the same period of 2022, driven by excision, MOHS light, and cryosurgery[188]. - Other Services revenue increased by approximately S$144,000, from S$718,000 for the six months ended June 30, 2021 to approximately S$862,000 for the same period in 2022[188]. Operational Costs and Expenses - Employee benefits expense amounted to approximately S$4,274,000, reflecting an increase of approximately S$1,585,000 or 58.9% due to additional headcounts[10]. - The company incurred professional and consulting fees of S$2,100,000, an increase from S$1,623,000 in the prior year[102]. - Total consumables and medical supplies used amounted to approximately S$2,597,000 for the six months ended June 30, 2022, up from S$722,000 in 2021, reflecting increased revenue from Prescription and Dispensing Services[191]. - Depreciation and amortization expenses totaled S$1,935,000, reflecting ongoing investments in plant and equipment and intangible assets[24]. - The total compensation for key management personnel during the period was S$1,235,000, up from S$787,000 in the previous year, representing a 57% increase[170]. Assets and Liabilities - As of June 30, 2022, total assets amounted to S$17,619,000, an increase from S$9,634,000 as of December 31, 2021[17]. - Net current assets increased to S$4,257,000 from S$2,777,000, reflecting improved liquidity[17]. - The company’s net assets increased to S$6,713,000 from S$4,567,000, indicating a stronger equity position[17]. - Trade receivables as of 30 June 2022 amounted to S$3,096,000, with a loss allowance of S$995,000, compared to S$2,230,000 and S$779,000 respectively in 2021, indicating an increase in both receivables and allowances[122]. - Total deposits increased to S$6,074,000 as of 30 June 2022, compared to S$1,958,000 in the previous year, reflecting a significant increase of 210%[122]. - The Group's total trade and other receivables amounted to S$12,587,000 as of 30 June 2022, compared to S$5,766,000 in 2021, indicating a substantial increase of 118%[122]. - Trade payables increased significantly to S$8,498,000 as of June 30, 2022, compared to S$3,259,000 as of December 31, 2021[154]. - The total amount of trade receivables that are not past due is S$634,000, while those overdue between 91 to 120 days amount to S$124,000[134]. Cash Flow and Financing - Operating cash flows before working capital changes were negative at S$1,639,000, indicating challenges in cash generation[24]. - Cash used in operating activities was S$3,706,000, up from S$1,996,000 in the previous year, highlighting increased operational cash outflows[24]. - Cash used in investing activities amounted to S$2,406,000, a significant increase from S$783,000 in the previous period[27]. - Cash from financing activities totaled S$5,210,000, up from S$2,861,000 in the previous period[27]. - The cash and cash equivalents at the end of the period were S$1,030,000, a decrease from S$4,871,000 at the end of the previous period[27]. - The company reported a repayment of borrowings totaling S$726,000, compared to S$181,000 in the prior period[27]. - The company has a loan of S$3 million with a repayment period of 60 months, which commenced on June 22, 2020, secured by a corporate guarantee[162]. - The total borrowings as of June 30, 2022, amounted to S$6,112,000, slightly up from S$6,067,000 as of December 31, 2021, indicating a marginal increase of 0.74%[158]. Credit Risk and Impairment - The Group recognizes expected credit losses (ECL) on financial assets subject to impairment under IFRS 9, including trade and other receivables, finance lease receivables, and cash equivalents[39]. - The Group always recognizes lifetime ECL for trade receivables and lease receivables, estimating losses using a provision matrix based on historical credit loss experience[39]. - The expected credit loss rate for trade receivables is less than 1%, indicating a low risk of default among customers[135]. - The ageing analysis of trade receivables shows that S$1,284,000 is overdue by more than 90 days, contributing to a total of S$2,101,000 in trade receivables[137]. - Credit-impaired financial assets are identified when events negatively impact the estimated future cash flows, such as significant financial difficulty of the borrower or breach of contract[53]. Strategic Developments - The Group has established a Mohs Micrographic Surgery Centre and a Mole Mapping Centre at Orchard Clinic, employing 3 Mohs Dermato-Surgeons, and opened a new dermatology clinic at Gleneagles Medical Centre in Singapore[183]. - The Group anticipates continued revenue improvement from clinics in Singapore and Hong Kong due to easing government anti-COVID-19 measures and mass vaccination rollouts[183]. - The Group has decided to suspend business development for its wholly-owned subsidiary, RMH Imaging Limited, due to significant market changes and differing future prospects[183]. - The management believes that the significant impairment in the investment portfolio will not have a continuous impact on the principal businesses and long-term operations of the Group[176]. - The Group is cautiously optimistic about rebounding strongly to profitability in 2022 due to a reasonably healthy cash reserve and intact business operations[182].

Financial Performance - The unaudited revenue of RMH Holdings Limited for the three months ended March 31, 2022, was approximately S$3,311,000, representing an increase of approximately S$1,151,000 or 53.3% compared to S$2,160,000 for the same period in 2021[7][11]. - The unaudited loss for the Group was approximately S$2,529,000 for the three months ended March 31, 2022, which is an increase of approximately S$1,621,000 or 178.5% compared to a loss of S$908,000 for the same period in 2021[8][11]. - Loss per share for the Company was approximately 0.27 Singapore cents for the three months ended March 31, 2022, compared to approximately 0.13 Singapore cents for the same period in 2021[9][11]. - The total comprehensive loss for the period was S$2,529,000, reflecting the overall financial performance of the Group[13]. - The Group's other operating income for the three months ended March 31, 2022, was S$223,000, compared to S$295,000 for the same period in 2021[13]. - The total comprehensive loss includes a foreign currency translation income of S$22,000 for the period[13]. - The Group's total equity as of March 31, 2022, was S$9,253,000, reflecting the financial position of the Company[15]. - The increase in losses was attributed to higher operating expenses and costs associated with the Group's activities during the period[8][11]. Revenue Breakdown - Revenue for the three months ended March 31, 2022, was S$3,311,000, representing a 53% increase from S$2,160,000 in the same period of 2021[36]. - Aesthetic services revenue increased to S$149,000 from S$88,000, a growth of 69% year-over-year[36]. - Consultation services revenue rose to S$541,000, up 21% from S$448,000 in the previous year[36]. - Trading sales surged to S$760,000 compared to S$31,000 in the same period last year, indicating a significant increase[36]. - Revenue recognized at a point in time was S$1,990,000, up from S$1,033,000, reflecting a 92% increase[36]. - Revenue recognized over time was S$1,321,000, compared to S$1,127,000, marking a 17% increase[36]. - Revenue from Singapore was S$2,551,000, up from S$2,160,000 in 2021, while revenue from Hong Kong was S$760,000, which was not reported in the previous year[42]. - Revenue from Aesthetic Services rose by approximately S$61,000 from S$88,000 for the three months ended March 31, 2021 to S$149,000 for the three months ended March 31, 2022[73]. - Revenue from Consultation Services increased by approximately S$93,000 from S$448,000 for the three months ended March 31, 2021 to S$541,000 for the three months ended March 31, 2022, with patient visits rising by 22.1%[75]. - Revenue from Prescription and Dispensing Services increased by approximately S$211,000 from S$675,000 in Q1 2021 to S$886,000 in Q1 2022, reflecting an increase in patient visits[77]. - Revenue from Treatment Services rose by approximately S$39,000 from S$591,000 in Q1 2021 to S$630,000 in Q1 2022, driven by excision, skin check, kenacort, and cryosurgery[77]. - Revenue from Other Services increased by approximately S$18,000 from S$327,000 in Q1 2021 to S$345,000 in Q1 2022, primarily from laboratory tests and medical examinations[77]. - Trading Sales contributed approximately S$760,000 in Q1 2022, an increase of approximately S$729,000 compared to S$31,000 in Q1 2021[77]. Operating Expenses - The company reported a loss before tax, with significant expenses including professional and consulting fees amounting to S$1,122,000, compared to S$717,000 in 2021[53]. - Employee benefits expense rose to S$1,951,000 in Q1 2022 from S$1,175,000 in Q1 2021, largely due to additional dermatologists[83]. - Other operating expenses increased by approximately S$1,008,000 or 119% from S$847,000 in Q1 2021 to S$1,855,000 in Q1 2022[93]. - Other operating income decreased by S$72,000 from approximately S$295,000 in Q1 2021 to approximately S$223,000 in Q1 2022[80]. - Consumables and medical supplies used increased to approximately S$1,138,000 in Q1 2022 from S$330,000 in Q1 2021, in line with revenue growth[80]. - Other expenses increased due to nonrecurring marketing and advertising expenses aimed at creating market awareness for the new aesthetic clinic[99]. Corporate Governance - The company adopted the Corporate Governance Code and complied with all applicable provisions during the three months ended March 31, 2022[120]. - The board is committed to high standards of corporate governance to manage business risks and enhance transparency[119]. - The Audit Committee consists of three independent non-executive Directors, ensuring compliance with GEM Listing Rules[128]. - The Audit Committee reviewed the Group's unaudited condensed consolidated financial statements for the three months ended March 31, 2022[129]. - All directors confirmed compliance with the required standard of dealings regarding securities transactions during the reporting period[123]. - The board will continue to review and improve the company's corporate governance practices[119]. Shareholder Information - The company had a significant shareholder, Dr. Loh Teck Hiong, holding 210,024,000 shares, representing 16.21% of the company[104]. - As of March 31, 2022, Brisk Success holds 210,024,000 shares, representing a 16.21% interest in the company[115]. - HK MZ Health Investment holds 132,968,000 shares, accounting for 10.26% of the company's interest[115]. - No share options were granted by the company from September 22, 2017, to the date of the report[123]. - The company and its subsidiaries did not purchase, sell, or redeem any shares during the three months ended March 31, 2022[123]. - No rights to acquire shares or debentures were granted to directors or their family members during the reporting period[123]. - The company has not disclosed any interests or short positions in shares that require disclosure under the SFO as of March 31, 2022[118]. Future Outlook - The company continues to focus on strategic initiatives to enhance its market position and operational efficiency moving forward[11]. - The Group expects continued improvement in revenue at a faster rate from clinics in both Singapore and Hong Kong due to easing COVID-19 measures[65]. - The Company is cautiously optimistic about returning to profitability in the second quarter of 2022[65]. - The sales of Regenerative Medicine products remained lackluster due to the continued closure of the Hong Kong-China border[65].

Financial Performance - The group's unaudited revenue for the nine months ended September 30, 2021, was approximately SGD 7,491,000, an increase of about SGD 2,665,000 or 55.2% compared to SGD 4,826,000 for the same period in 2020[4]. - The group's unaudited loss for the nine months ended September 30, 2021, was approximately SGD 4,171,000, an increase of about SGD 3,216,000 or 336.8% compared to a loss of SGD 955,000 for the same period in 2020[4]. - The loss per share for the nine months ended September 30, 2021, was approximately 0.58 Singapore cents, compared to a loss per share of 0.16 Singapore cents for the same period in 2020[4]. - Total comprehensive loss for the nine months ended September 30, 2021, was SGD 4,268,000, compared to a total comprehensive loss of SGD 980,000 for the same period in 2020[7]. - The total loss before tax for the nine months ended September 30, 2021, was SGD 4,031,000, compared to a loss of SGD 1,067,000 for the same period in 2020[43]. - The company reported a loss attributable to owners of SGD 4,171,000 for the nine months ended September 30, 2021, compared to a loss of SGD 955,000 for the same period in 2020[52]. Revenue Breakdown - Total revenue for medical services reached SGD 7,393,000 for the nine months ended September 30, 2021, compared to SGD 5,024,000 for the same period in 2020, representing a year-over-year increase of approximately 47.2%[41]. - Revenue from beauty services was SGD 399,000, while consultation services generated SGD 1,470,000, and prescription and dispensing services contributed SGD 2,181,000 for the nine months ended September 30, 2021[41]. - Other service revenue increased from approximately SGD 503,000 for the nine months ended September 30, 2020, to approximately SGD 1,116,000 for the nine months ended September 30, 2021, representing a growth of about 121%[63]. - Revenue from consultation services increased from approximately SGD 980,000 to SGD 1,470,000, with patient visits rising by about 41.2% from 12,537 to 17,708[62]. Expenses and Costs - Employee benefit expenses amounted to approximately SGD 4,196,000, an increase of about SGD 2,448,000 or 140% compared to SGD 1,748,000 for the same period in 2020[4]. - The company’s interest expenses for borrowings increased to SGD 143,000 from SGD 31,000 in the previous year[7]. - The cost of consumables and medical supplies rose from approximately SGD 759,000 for the nine months ended September 30, 2020, to approximately SGD 1,342,000 for the nine months ended September 30, 2021, an increase of about 77%[64]. - Other operating expenses increased by approximately SGD 536,000 or 15.5%, from about SGD 3,450,000 for the nine months ended September 30, 2020, to approximately SGD 3,986,000 for the nine months ended September 30, 2021[74]. Corporate Governance and Compliance - The company has complied with all applicable corporate governance code provisions for the nine months ending September 30, 2021[99]. - The board of directors consists of five members, including three executive directors and two independent non-executive directors, following recent changes in board composition[98]. - The company is committed to maintaining high standards of corporate governance to manage business risks and enhance transparency[95]. - The audit committee has reviewed the unaudited condensed consolidated financial statements for the nine months ending September 30, 2021, and provided opinions and recommendations[110]. Dividends and Share Placement - The board does not recommend the payment of any dividend for the nine months ended September 30, 2021[4]. - The company plans to issue up to 144,000,000 placement shares at a price of HKD 0.135 per share as part of a placement agreement signed on September 27, 2021[82]. - The company successfully placed 144,000,000 new shares at a price of HKD 0.135 per share, increasing total shares from 720,000,000 to 864,000,000[84]. - The net proceeds from the placement amounted to approximately HKD 19,148,000, with 40% allocated for purchasing medical imaging equipment, 30% for general working capital, and 30% for potential investments[84]. Financial Reporting and Standards - The unaudited consolidated financial statements for the nine months ended September 30, 2021, were prepared in accordance with International Financial Reporting Standards and presented in Singapore dollars[14]. - The group adopted all new and revised International Financial Reporting Standards effective for annual periods beginning on or after January 1, 2021, with no significant impact on accounting policies or reported amounts[17]. - The financial statements were prepared based on historical cost, with fair value measurements considered for assets and liabilities[18]. - The group recognized expected credit losses for debt instruments measured at amortized cost or fair value through other comprehensive income, updating the expected credit loss amounts at each reporting date[22]. Operational Developments - The company established a Mohs micrographic surgery center and a Mole Mapping center, enhancing its service offerings with three Mohs dermatologists[56]. - The company acquired a Siemens Healthineers MAGNETOM Lumina and a Revolution CT, aiming to expand its medical imaging services[57]. - The company plans to enhance its service offerings through the acquisition of new medical equipment focused on preventive and proactive care[86]. - The company has not reported any significant events affecting its operations since September 30, 2021[87].

Financial Performance - The group's unaudited revenue for the six months ended June 30, 2021, was approximately SGD 4,623,000, an increase of about SGD 1,289,000 or 38.7% compared to SGD 3,334,000 for the same period in 2020[5]. - The group reported an unaudited loss of approximately SGD 2,829,000 for the six months ended June 30, 2021, an increase of about SGD 1,776,000 or 169% compared to a profit of SGD 1,053,000 for the same period in 2020[5]. - For the six months ended June 30, 2021, the company reported a total comprehensive loss of SGD 2,829,000, compared to a total comprehensive loss of SGD 993,000 for the same period in 2020[11][13]. - The company reported a pre-tax loss of SGD 2,829,000 for the six months ended June 30, 2021, compared to a loss of SGD 1,053,000 in the same period in 2020, representing an increase in losses of approximately 168.5%[54]. - Basic loss per share for the six months ended June 30, 2021, was SGD 0.40, compared to SGD 0.17 for the same period in 2020, indicating a worsening in per-share performance[54]. Revenue Breakdown - Revenue from medical services reached SGD 4,623 thousand for the six months ended June 30, 2021, compared to SGD 3,334 thousand for the same period in 2020, representing a year-over-year increase of approximately 38.6%[45]. - Revenue from beauty services was SGD 231 thousand, while consultation services generated SGD 946 thousand, and prescription and dispensing services contributed SGD 1,406 thousand for the first half of 2021[45]. - Revenue from consultation services increased from SGD 665,000 for the six months ended June 30, 2020, to SGD 946,000 for the same period in 2021, reflecting an increase of 281,000 or 42.3%[91]. - Revenue from prescription and dispensing services rose from SGD 1,008,000 to SGD 1,406,000, an increase of SGD 398,000 or 39.4%[91]. - Revenue from treatment services increased from SGD 977,000 to SGD 1,267,000, a rise of SGD 290,000 or 29.6%[91]. - Other services revenue grew from SGD 340,000 to SGD 718,000, an increase of SGD 378,000 or 111.2%[92]. Expenses and Costs - Employee benefit expenses amounted to approximately SGD 2,689,000, an increase of about SGD 1,728,000 or 179.8% compared to SGD 961,000 for the same period in 2020[5]. - The company incurred professional and consulting expenses of SGD 1,623,000 for the six months ended June 30, 2021, slightly down from SGD 1,630,000 in the same period of 2020[51]. - Other operating expenses increased by approximately SGD 571,000 or 29% to SGD 2,562,000 for the six months ended June 30, 2021[104]. Assets and Liabilities - Total assets less current liabilities amounted to SGD 14,287,000 as of June 30, 2021, compared to SGD 12,118,000 as of December 31, 2020[9]. - The net assets of the company were SGD 7,199,000 as of June 30, 2021, compared to SGD 5,531,000 as of December 31, 2020[9]. - Current liabilities totaled SGD 10,242,000 as of June 30, 2021, compared to SGD 9,626,000 as of December 31, 2020[9]. - The company's cash and cash equivalents decreased to SGD 4,871,000 as of June 30, 2021, down from SGD 7,639,000 at the end of June 2020[13]. - The company recorded a net cash outflow from operating activities of approximately SGD 1,996,000 for the six months ended June 30, 2021, compared to SGD 2,928,000 for the same period in 2020[114]. Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2021[5]. - The company did not recommend an interim dividend for the six months ended June 30, 2021, consistent with the previous year[55]. - As of June 30, 2021, Dr. Loh Teck Hiong holds 278,848,000 shares, representing 38.73% of the company's equity[129]. - Brisk Success Holdings Limited, controlled by Dr. Loh, is the beneficial owner of the 278,848,000 shares, also accounting for 38.73% of the company's equity[131]. Strategic Initiatives - The company plans to diversify its services and product offerings through acquisitions, particularly in Hong Kong, the Greater Bay Area, Singapore, and ASEAN countries[118]. - The group anticipates a strong rebound in profitability in 2021 due to the easing of COVID-19 restrictions and rapid vaccination rollout[87]. - The company plans to strategically expand clinics outside of Singapore with an investment of around HKD 1.0 million, expecting significant revenue contributions post-vaccination in Hong Kong[126]. Compliance and Governance - The company has complied with all applicable corporate governance codes during the six months ending June 30, 2021[134]. - All directors confirmed compliance with the trading code during the six months ending June 30, 2021[141]. - The company has adhered to the non-competition commitments made by its controlling shareholders as of June 30, 2021[143].

Financial Performance - The group's unaudited revenue for the three months ended March 31, 2021, was approximately SGD 2,160,000, an increase of about SGD 260,000 or 13.7% compared to SGD 1,900,000 for the same period in 2020[3]. - The group's unaudited loss for the three months ended March 31, 2021, was approximately SGD 908,000, an increase of about SGD 667,000 or 276.8% compared to a loss of SGD 241,000 for the same period in 2020[3]. - The total comprehensive loss for the three months ended March 31, 2021, was SGD 960,000, compared to SGD 171,000 for the same period in 2020[7]. - The company reported a pre-tax loss of SGD 908,000 for the three months ended March 31, 2021, compared to a loss of SGD 171,000 for the same period in 2020[47]. - The company recorded a loss of approximately SGD 889,000 for the three months ended March 31, 2021, compared to a loss of approximately SGD 186,000 for the same period in 2020, an increase in loss of about SGD 703,000[75]. Revenue Breakdown - Revenue from aesthetic services reached SGD 88,000, up from SGD 25,000 in Q1 2020, marking a significant increase of 252%[38]. - Consultation services generated SGD 448,000, compared to SGD 420,000 in the previous year, reflecting a growth of about 6.67%[38]. - Prescription and dispensing services revenue was SGD 675,000, an increase from SGD 586,000, which is a growth of approximately 15.19%[38]. - Revenue from treatment services was SGD 591,000, slightly down from SGD 603,000, indicating a decrease of about 1.99%[38]. - Other services, primarily laboratory tests during treatment, generated SGD 327,000, up from SGD 266,000, representing a growth of approximately 22.93%[38]. - Trade sales amounted to SGD 31,000, a new revenue stream compared to SGD 0 in Q1 2020[38]. - Revenue recognized at a point in time was SGD 1,033,000, an increase from SGD 852,000, reflecting a growth of approximately 21.25%[38]. - Revenue recognized over a period was SGD 1,127,000, compared to SGD 1,048,000, indicating a growth of about 7.54%[38]. Expenses and Costs - Employee benefit expenses for the three months ended March 31, 2021, were SGD 1,175,000, significantly higher than SGD 478,000 for the same period in 2020[5]. - Other operating expenses rose by approximately SGD 58,000 or 7% to SGD 847,000 for the three months ended March 31, 2021, compared to SGD 789,000 for the same period in 2020[69]. - The cost of consumables and medical supplies rose from SGD 318,000 to SGD 330,000, reflecting an increase in revenue from prescription and dispensing services[60]. - Interest expenses on borrowings amounted to SGD 47,000 for the three months ended March 31, 2021, with lease liabilities interest expenses at SGD 46,000, down from SGD 68,000 in the previous year[42]. - Income tax expenses decreased to approximately SGD 19,000 for the three months ended March 31, 2021, from approximately SGD 55,000 for the same period in 2020, mainly due to an increase in pre-tax losses[74]. Equity and Dividends - The total equity as of March 31, 2021, was SGD 9,124,000, an increase from SGD 5,531,000 as of January 1, 2021[7]. - The board does not recommend the payment of any dividend for the three months ended March 31, 2021[3]. - The company did not recommend any dividend for the three months ended March 31, 2021, consistent with the previous year[48]. Governance and Compliance - The company has adopted the corporate governance code and has complied with all applicable provisions for the three months ended March 31, 2021[83]. - The audit committee reviewed the unaudited condensed consolidated financial statements for the three months ended March 31, 2021[96]. - The company is actively seeking suitable candidates to fill the vacancies on the board to comply with GEM listing rules[84]. - The board of directors confirmed compliance with the trading code for directors during the three months ended March 31, 2021[90]. - There were no interests held by directors or controlling shareholders in any competing businesses as of March 31, 2021[93]. Credit Risk and Financial Assets - Expected credit losses are recognized for financial assets, including trade and other receivables, financing lease receivables, and cash and cash equivalents, in accordance with IFRS 9[16]. - The group estimates expected credit losses using a provision matrix based on historical credit loss experience and adjusts for various factors, including current and forecasted economic conditions[16]. - A significant increase in credit risk is assessed by comparing the default risk of financial instruments at the reporting date with that at initial recognition[19]. - The group assumes that credit risk has significantly increased if contractual payments are overdue by more than 30 days, unless there is reasonable evidence to the contrary[20]. - Financial assets are considered to be in default if they are overdue by more than 90 days, based on past repayment records and the debtor's situation[22]. Lease and Asset Management - The group recognizes right-of-use assets and corresponding lease liabilities for all lease arrangements, excluding short-term leases and low-value asset leases[25]. - Lease liabilities are initially measured at the present value of lease payments that are not yet paid, discounted using the implicit rate of the lease or the incremental borrowing rate[25]. - The company did not make any adjustments to lease liabilities during the reported period[28]. Shareholding and Ownership - The company’s board member Loh Teck Hiong holds a 38.73% equity interest in the company through Brisk Success Holdings Limited, which owns 278,848,000 shares[77]. - As of March 31, 2021, Brisk Success holds 278,848,000 shares, representing 38.73% of the company's equity[80]. - Fung Yuen Yee, as the spouse of Dr. Loh, is deemed to have the same equity interest of 278,848,000 shares, also 38.73%[81]. - The company has not granted any share options since the adoption of the share option scheme on September 22, 2017[87]. - No purchases, sales, or redemptions of the company's shares were made by the company or its subsidiaries during the three months ended March 31, 2021[88].

Financial Performance - The company recorded a loss of approximately SGD 9.27 million for the year ended December 31, 2020, a decrease of about SGD 9.43 million compared to a profit of approximately SGD 158,000 for the year ended December 31, 2019[25]. - The group’s revenue increased by approximately SGD 584,000 or 8.1% to approximately SGD 7,809,000 for the year ended December 31, 2020, compared to SGD 7,225,000 for the year ended December 31, 2019[34]. - Revenue from beauty services rose from SGD 124,000 in 2019 to SGD 220,000 in 2020, an increase of SGD 96,000[34]. - Revenue from consultation services decreased by SGD 515,000 from SGD 1,843,000 in 2019 to SGD 1,328,000 in 2020, with patient visits dropping from 18,622 to 17,074, a decline of 8.9%[35]. - Revenue from prescription and dispensing services fell by SGD 161,000 from SGD 2,110,000 in 2019 to SGD 1,949,000 in 2020[35]. - Trade sales revenue, primarily from the DS brand dermatology clinic's ALL-DAY HAND SANITISER and disposable medical masks, contributed SGD 1,785,000 in 2020[36]. - The company recorded a loss of approximately SGD 9,272,000 for the year ended December 31, 2020, a decrease of approximately 5,968% compared to a profit of SGD 158,000 in 2019[52]. - Total equity as of December 31, 2020, was approximately SGD 5,531,000, down from approximately SGD 14,744,000 in 2019[54]. - Cash and cash equivalents as of December 31, 2020, were approximately SGD 4,932,000, compared to approximately SGD 12,651,000 in 2019[54]. - The net cash used in operating activities for the year was approximately SGD 4,515,000, compared to a net cash generated of approximately SGD 330,000 in 2019[54]. Business Expansion and Development - The company has established a joint venture in Hong Kong to create a comprehensive specialty center focusing on dermatology, aesthetic medicine, health check-ups, and gynecology services[24]. - The company opened a new clinic in Paragon, focusing on laser and aesthetic dermatology, accelerating its development in the aesthetic medicine field[24]. - The company operates five dermatology and surgical clinics in Singapore and has established a regenerative medicine center in Kowloon Bay, targeting clients in the Greater Bay Area[30]. - The group anticipates stable growth in Singapore's business with the opening of new clinics and recruitment of four new dermatologists[32]. - The group expects significant revenue contributions from new businesses in Hong Kong's beauty laser center and regenerative medicine center once the border with mainland China reopens later this year[32]. - The group plans to strategically expand and enhance its clinic network outside of Singapore, reallocating approximately HKD 5 million for identifying acquisition targets and seeking collaboration opportunities[72]. - The group has successfully obtained an offer letter dated February 1, 2021, to open a new clinic at Eagle Medical Center, expanding into more areas and establishing a dermatology specialty clinic[72]. - Approximately HKD 4.2 million has been reallocated for investment in medical technology and digital healthcare, aiming to create synergies with existing operations[72]. - The group recognizes the high demand for healthcare services from patients in mainland China, particularly in the Greater Bay Area, and sees potential benefits from expanding in Hong Kong[71]. Employee and Operational Costs - Employee benefits expenses increased from SGD 2,322,000 in 2019 to SGD 3,884,000 in 2020, primarily due to hiring additional staff for the Hong Kong clinic[41]. - The total number of employees (excluding doctors) increased from 30 in 2019 to 44 in 2020[42]. - The cost of consumables and medical supplies rose from SGD 1,140,000 in 2019 to SGD 2,467,000 in 2020, an increase of approximately 116%[39]. - Other operating expenses increased by approximately 108.2% from SGD 2,066,000 in 2019 to SGD 4,302,000 in 2020[45]. - Professional and consulting fees rose by approximately SGD 2,413,000, primarily related to professional fees payable to doctors[46]. - Employee costs, including directors' remuneration, amounted to approximately SGD 3,884,000 in 2020, up from approximately SGD 2,322,000 in 2019[61]. - The company had a leverage ratio of approximately 102.57% as of December 31, 2020, indicating significant debt relative to equity[54]. Shareholder and Governance Information - Loh Teck Hiong holds 278,848,000 shares, representing 46.47% of the company's equity[107]. - The company has adopted a share option scheme allowing for the issuance of up to 60,000,000 shares, which is approximately 8.33% of the total issued share capital[117]. - The company has confirmed compliance with non-competition commitments by its major shareholders as of December 31, 2020[127]. - The annual general meeting is scheduled for May 11, 2021, with a suspension of share transfer registration from May 6 to May 11, 2021[128]. - The company completed a placement of up to 120,000,000 shares at a price of HKD 0.225 per share, raising approximately HKD 12,000,000 for general working capital[134]. - The total issued share capital of the company increased to 720,000,000 shares following the placement[134]. - The company has a public float of at least 25% of its total issued share capital as of the last practicable date before the report was published[132]. - There were no related party transactions that required disclosure under GEM listing rules for the year ended December 31, 2020[133]. - The board consists of six directors, including three executive directors and three independent non-executive directors as of the report date[153]. - The company has adopted the principles and code provisions of the corporate governance code as set out in the GEM Listing Rules Appendix 15, and has complied with all applicable code provisions for the year ended December 31, 2020[151]. - The company has appointed at least three independent non-executive directors, representing more than one-third of the board, in compliance with GEM Listing Rules[154]. Compliance and Risk Management - The company emphasizes the importance of compliance with regulatory requirements and has maintained significant compliance with applicable laws and regulations during the reporting period[84]. - The company has a robust internal control system and risk management procedures in place, as monitored by the board[155]. - The independent non-executive directors contribute valuable expertise and independent judgment to the board's strategic decisions[155]. - The internal auditor, Moore Stephen LLP, has confirmed the effectiveness of the internal control and risk management systems, with no significant deficiencies reported[181]. ESG and Stakeholder Engagement - The first ESG report outlines the company's commitment to sustainable development and responsible business practices, highlighting its impact on stakeholders[195]. - The reporting period for the ESG data and activities covers January 1 to December 31, 2020[197]. - The company recognizes the strategic role of stakeholders in maintaining long-term growth and responsible business development[198]. - The company encourages stakeholder feedback on its ESG policies and performance, providing a dedicated email for communication[199].

Financial Performance - The group's unaudited revenue for the nine months ended September 30, 2020, was approximately SGD 4,826,000, a decrease of about SGD 600,000 or 11.1% compared to SGD 5,426,000 for the same period in 2019[4] - The group reported an unaudited loss of approximately SGD 955,000 for the nine months ended September 30, 2020, a decrease of SGD 1,648,000 or 237.8% compared to a profit of SGD 693,000 for the same period in 2019[4] - The loss per share for the nine months ended September 30, 2020, was (0.16) Singapore cents, compared to earnings of 0.12 Singapore cents for the same period in 2019[4] - The group's total comprehensive loss for the nine months ended September 30, 2020, was SGD 980,000, compared to total comprehensive income of SGD 693,000 for the same period in 2019[6] - The company reported a loss attributable to owners of SGD 955,000 for the nine months ended September 30, 2020, compared to a profit of SGD 693,000 for the same period in 2019, resulting in a loss per share of SGD 0.16[53] - The company reported a loss from joint ventures of SGD 709,000 for the nine months ended September 30, 2020[55] - The company recorded a loss of approximately SGD 955,000 for the nine months ended September 30, 2020, a decrease of about SGD 1,648,000 or 237.8% compared to a profit of SGD 693,000 for the same period in 2019[79] Revenue Breakdown - Total revenue for the nine months ended September 30, 2020, was SGD 4,826,000, a decrease from SGD 5,426,000 in the same period of 2019, representing a decline of approximately 11%[44] - Revenue from consultation services was SGD 980,000, while prescription and dispensing services generated SGD 1,487,000, and treatment services brought in SGD 1,400,000 for the nine months ended September 30, 2020[44] - The company experienced a decrease in revenue from consultation services, which accounted for 20.3% of total revenue in 2020, down from 26.3% in 2019[60] Expenses and Costs - Employee benefit expenses for the nine months ended September 30, 2020, were SGD 1,748,000, compared to SGD 1,504,000 for the same period in 2019[6] - The cost of consumables and medical supplies for the nine months ended September 30, 2020, was SGD 759,000, compared to SGD 839,000 for the same period in 2019[62] - Professional and consulting fees surged to SGD 2,586,000 for the nine months ended September 30, 2020, compared to SGD 755,000 in the previous year[50] - Other operating expenses surged by 130.0% to SGD 3,450,000 for the nine months ended September 30, 2020, from SGD 1,500,000 in the previous year[71] - Employee benefits expenses increased to SGD 1,748,000 for the nine months ended September 30, 2020, up from SGD 1,504,000 for the same period in 2019, representing a growth of approximately 16.2%[65] Corporate Governance and Compliance - The company confirmed compliance with all applicable corporate governance code provisions for the nine months ended September 30, 2020[88] - The audit committee reviewed the unaudited condensed consolidated financial statements for the nine months ended September 30, 2020[101] - The company appointed a new independent non-executive director on June 8, 2020, ensuring compliance with GEM listing rules[87] - The company has maintained a high standard of corporate governance to manage business risks and enhance transparency[87] - The company has adopted a code of conduct for securities transactions by directors, confirming compliance throughout the reporting period[92] Future Outlook - The company expects revenue to continue to recover for the remainder of the year as Singapore's economy reopens and new operations in Hong Kong begin to contribute to revenue[58] - The company plans to continue developing and launching its own skincare products and nutritional supplements for sale in its clinics and directly to the public[58] - The company plans to expand its multi-specialty center focused on dermatology, aesthetics, preventive and regenerative medicine, and obstetrics and gynecology services in Hong Kong[75] Other Financial Information - The company incurred finance costs of SGD 31,000 for the nine months ended September 30, 2020, compared to no finance costs for the same period in 2019[6] - Interest income from financing leases was SGD 31,000, while interest income from other sources was SGD 348,000 in the previous year[46] - Lease liability interest expenses increased to SGD 134,000 for the nine months ended September 30, 2020, compared to SGD 61,000 in the same period of 2019[48] - Income tax expenses decreased to approximately SGD 166,000 for the nine months ended September 30, 2020, down from SGD 210,000 in the previous year, attributed to a pre-tax loss of approximately SGD 789,000[78]

Financial Performance - The group's unaudited revenue for the six months ended June 30, 2020, was approximately SGD 3,334,000, a decrease of about SGD 137,000 or 3.9% compared to SGD 3,471,000 for the same period in 2019[3]. - The group reported an unaudited loss of approximately SGD 1,053,000 for the six months ended June 30, 2020, a decline of about SGD 1,386,000 or 416.2% compared to a profit of SGD 333,000 for the same period in 2019[3]. - The loss per share for the six months ended June 30, 2020, was (0.17) Singapore cents, compared to earnings of 0.06 Singapore cents for the same period in 2019[3]. - Total revenue for the six months ended June 30, 2020, was 3,334 thousand Singapore dollars, a decrease of 3.95% from 3,471 thousand Singapore dollars in the same period of 2019[47]. - The company incurred a pre-tax loss of 1,012 thousand Singapore dollars for the six months ended June 30, 2020, compared to a profit of 333 thousand Singapore dollars in the same period of 2019[55]. - The company recorded a loss of approximately SGD 1,053,000 for the six months ended June 30, 2020, a decrease of about SGD 1,386,000 or 416.2% compared to a profit of approximately SGD 333,000 for the same period in 2019[107]. Assets and Liabilities - Total assets less current liabilities as of June 30, 2020, amounted to SGD 18,566,000, down from SGD 22,539,000 as of December 31, 2019[9]. - Non-current assets as of June 30, 2020, were SGD 11,175,000, a slight decrease from SGD 11,925,000 as of December 31, 2019[9]. - Current assets as of June 30, 2020, totaled SGD 12,087,000, compared to SGD 13,729,000 as of December 31, 2019[9]. - The group’s total liabilities as of June 30, 2020, were SGD 4,815,000, down from SGD 7,795,000 as of December 31, 2019[9]. - The group’s equity as of June 30, 2020, was SGD 13,751,000, compared to SGD 14,744,000 as of December 31, 2019[9]. - The group had a total debt of approximately SGD 3,000,000 in secured bank loans as of June 30, 2020, resulting in a debt-to-equity ratio of approximately 21.5%[110]. Cash Flow - For the six months ended June 30, 2020, the operating cash flow used was SGD (2,928) thousand, compared to SGD 359 thousand for the same period in 2019, indicating a significant decline[16]. - The total cash and cash equivalents at the end of the period were SGD 7,639 thousand, down from SGD 12,974 thousand at the end of the previous period[16]. - The net cash used in investing activities was SGD (4,308) thousand, which included SGD (2,570) thousand for the purchase of property and equipment and SGD (1,678) thousand for the acquisition of joint ventures[16]. - Financing activities generated cash inflow of SGD 2,163 thousand, primarily from new bank loans of SGD 3,000 thousand, offset by repayments of borrowings and lease liabilities[16]. - The net cash used in operating activities for the six months ended June 30, 2020, was approximately SGD 2,928,000, compared to a net cash inflow of approximately SGD 359,000 for the same period in 2019[111]. Revenue Breakdown - The main sources of revenue include consulting services, prescription and dispensing services, treatment services, and cosmetic services[41]. - Consultation services revenue decreased to 665 thousand Singapore dollars, down 28.2% from 926 thousand Singapore dollars in the previous year[47]. - Prescription and dispensing services revenue increased to 1,352 thousand Singapore dollars, up 37.2% from 985 thousand Singapore dollars in the previous year[47]. - Revenue from consultation services was SGD 665,000, accounting for 19.9% of total revenue, down from SGD 926,000 or 26.7% in the previous year[88]. - Revenue from prescription and dispensing services increased to SGD 1,352,000, representing 40.6% of total revenue, compared to SGD 985,000 or 28.4% in the prior year[88]. Operational Challenges - The company experienced significant operational challenges due to COVID-19, including reduced capacity in Singapore clinics and delayed openings of new clinics in Hong Kong[83]. - The company has implemented telemedicine services and sold antiviral products to mitigate the impact of the pandemic[83]. - The number of patients seeking consultation decreased from 6,401 in the six months ended June 30, 2019, to 5,771 in the same period of 2020, representing a decline of 9.8%[87]. - Other operating expenses rose by approximately SGD 952,000 or 91.6% to SGD 1,991,000 for the six months ended June 30, 2020, compared to SGD 1,039,000 in the previous year[100]. Corporate Governance - The company has complied with all applicable corporate governance code provisions during the six months ending June 30, 2020[130]. - The number of independent non-executive directors fell below the minimum required by GEM Listing Rules after the resignation of a director, but compliance was restored with a new appointment on June 8, 2020[130]. - The company has adopted a code of conduct for directors' securities transactions, which complies with GEM Listing Rules[135]. - The audit committee was established on September 22, 2017, and consists of three independent non-executive directors, ensuring compliance with GEM Listing Rule 5.28 and Corporate Governance Code C.3[142]. - The audit committee reviewed the unaudited condensed consolidated financial statements for the six months ended June 30, 2020, and provided opinions and recommendations[142]. Future Plans - The company plans to expand its non-prescription product range for skincare and general health, leveraging lessons learned from the COVID-19 pandemic[86]. - The company is actively exploring acquisition targets and partnership opportunities in Hong Kong, the Greater Bay Area, Singapore, and ASEAN countries[86]. - The company aims to enhance online telemedicine capabilities and clinic operational automation in response to increasing patient demand[86]. - The company plans to strategically expand and enhance its clinic network outside of Singapore, with approximately HKD 5,000,000 reallocated for identifying acquisition targets and seeking collaboration opportunities[120]. - Approximately HKD 4,200,000 has been reallocated for investments in medical technology, digital healthcare, and AI deployment to create synergies with existing operations[122].

Financial Performance - The group's unaudited revenue for the three months ended March 31, 2020, was approximately SGD 1,900,000, representing a slight increase of SGD 138,000 or 7.8% compared to SGD 1,762,000 for the same period in 2019[5] - The group's unaudited loss for the three months ended March 31, 2020, was approximately SGD 241,000, a decrease of SGD 539,000 or 180.9% compared to a profit of SGD 298,000 for the same period in 2019[5] - Basic loss per share for the three months ended March 31, 2020, was (0.03) Singapore cents, compared to a profit of 0.05 Singapore cents for the same period in 2019[5] - The total comprehensive loss for the three months ended March 31, 2020, was SGD 241,000, compared to a total comprehensive income of SGD 298,000 for the same period in 2019[7] - The company incurred a pre-tax loss of SGD 171,000 for the three months ended March 31, 2020, compared to a profit of SGD 298,000 for the same period in 2019[49] Operating Expenses - Total operating expenses increased to SGD 789,000 for the three months ended March 31, 2020, compared to SGD 514,000 for the same period in 2019[7] - Employee benefit expenses rose to SGD 478,000 for the three months ended March 31, 2020, compared to SGD 402,000 for the same period in 2019[7] - Depreciation of property, plant, and equipment increased to SGD 90,000 for the three months ended March 31, 2020, compared to SGD 54,000 for the same period in 2019[7] - Other operating expenses increased by approximately SGD 275,000 or 53.5% to SGD 789,000 for the three months ended March 31, 2020, compared to SGD 514,000 for the same period in 2019[69] Revenue Breakdown - Revenue from consultation services was SGD 420,000, accounting for approximately 22.0% of total revenue, while prescription and dispensing services generated SGD 586,000, representing 31.0%[38] - Revenue from treatment services reached SGD 603,000, contributing about 32.0% to total revenue, and beauty services generated SGD 25,000, making up 1.0%[52] - Other services, primarily related to laboratory tests during treatment, accounted for SGD 266,000, or 14.0% of total revenue[39] - The increase in revenue was primarily driven by an increase in prescription and dispensing services and other services related to laboratory tests during treatment[52] - Revenue from consultation services decreased from SGD 488,000 to SGD 420,000, a decline of approximately 14%[55] - Revenue from prescription and dispensing services increased from SGD 495,000 to SGD 586,000, an increase of approximately 18.4%[57] - Revenue from treatment services decreased from SGD 658,000 to SGD 603,000, a decline of approximately 8.4%[57] Equity and Shareholder Information - The group's total equity as of March 31, 2020, was SGD 14,573,000, a decrease from SGD 14,744,000 as of January 1, 2020[9] - Loh Teck Hiong, a director, holds 310,000,000 shares, representing 51.66% of the company's equity, through a controlled corporation[77] - The total equity held by major shareholders includes Brisk Success with 310,000,000 shares (51.66%) and Fung Yuen Yee with 358,000,000 shares (59.66%) as spouse interests[81] Governance and Compliance - The company has adopted the corporate governance code as per GEM listing rules and has complied with all applicable provisions during the three months ended March 31, 2020[84] - The audit committee has reviewed the unaudited condensed consolidated financial statements for the three months ended March 31, 2020, and provided opinions and recommendations[100] - The audit committee consists of two independent non-executive directors, which is below the minimum number required by GEM Listing Rules[97] - The company is actively seeking suitable candidates to fill the vacancies in the board and committees to comply with GEM Listing Rules[97] - There were no interests held by directors or controlling shareholders in any competing businesses during the review period[92] - The compliance advisor, Choy Yau Capital Limited, had no interests related to the group that required disclosure under GEM Listing Rules as of March 31, 2020[93] - The company has adhered to the non-competition commitments made by its controlling shareholders as of March 31, 2020[91] Dividend Policy - The board does not recommend the payment of any dividend for the three months ended March 31, 2020[5] - The board of directors did not recommend any dividend for the three months ended March 31, 2020[50] - The board does not recommend the payment of dividends for the three months ended March 31, 2020[96] Future Outlook - The company plans to mitigate the impact of COVID-19 by selling and delivering antiviral products and launching telemedicine services[53] - The company expects to benefit from pent-up demand after the COVID-19 pandemic subsides[53] Credit Losses and Leases - The group confirms expected credit losses for debt instruments measured at amortized cost or fair value through other comprehensive income, with no impairment losses recognized for equity investments[21] - Expected credit losses are updated at each reporting date to reflect changes in credit risk since initial recognition, with full period expected credit losses recognized for trade receivables[21] - The group assesses whether a contract contains a lease at the contract's inception and recognizes right-of-use assets and corresponding lease liabilities for all leases, excluding short-term leases and low-value asset leases[24] - Lease liabilities are initially measured at the present value of lease payments not yet paid, discounted using the interest rate implicit in the lease or the incremental borrowing rate[24] - The group does not reclassify comparative information when applying the cumulative catch-up method under IFRS 16[23] - The group recognizes revenue when control of products or services is transferred to customers, measuring revenue based on the expected consideration to be received[31] - The group evaluates whether a right-of-use asset is impaired according to IAS 36, recognizing any identified impairment losses[30] - Lease liabilities are remeasured when there are changes in lease terms or significant events affecting the assessment of purchase options[27] - The group applies a provision for costs related to the dismantling and removal of leased assets as per IAS 37, with costs included in the related right-of-use asset[29] - The group does not account for variable lease payments that are not dependent on an index or rate when measuring lease liabilities and right-of-use assets[30]

Financial Performance - The group recorded a profit of approximately SGD 158,000 for the year ended December 31, 2019, a decrease of about SGD 1,693,000 compared to a profit of approximately SGD 1,851,000 for the year ended December 31, 2018[30]. - The group's total revenue for the year ended December 31, 2019, was approximately SGD 7,225,000, an increase of about SGD 238,000 or 3.4% compared to SGD 6,987,000 for the year ended December 31, 2018[39]. - The net profit for the year ended December 31, 2019, was approximately SGD 158,000, a decrease of about SGD 1,693,000 compared to the profit of approximately SGD 1,851,000 for the year ended December 31, 2018[55]. - The net cash generated from operating activities for the year ended December 31, 2019, was approximately SGD 330,000, down from approximately SGD 1,876,000 for the year ended December 31, 2018[57]. - The total equity as of December 31, 2019, was approximately SGD 14,744,000, compared to approximately SGD 14,606,000 as of December 31, 2018[57]. Revenue Breakdown - Revenue from consultation services reached SGD 1,843,000, accounting for 25.5% of total revenue, while prescription and dispensing services generated SGD 2,110,000, representing 29.2% of total revenue[39]. - Revenue from treatment services decreased to SGD 2,499,000 in 2019 from SGD 2,648,000 in 2018, mainly due to a decline in chemical peels and skin treatments[40]. - Other services revenue rose to SGD 649,000 in 2019, accounting for 9.0% of total revenue, compared to SGD 437,000 or 6.2% in 2018[39]. - Revenue from the top five customers accounted for 23.1% of total revenue, down from 29.0% in 2018[101]. - The largest customer contributed 12.4% of total revenue, compared to 13.9% in 2018[101]. Cost and Expenses - The increase in costs was primarily due to employee benefits, depreciation of property and equipment, and other professional fees[30]. - Employee benefits expenses increased to SGD 2,322,000 in 2019 from SGD 1,812,000 in 2018, primarily due to hiring additional staff for beauty clinics and the "Family and Skin" clinic[45]. - Other operating expenses increased by approximately SGD 172,000 or 9.1% from SGD 1,894,000 for the year ended December 31, 2018, to SGD 2,066,000 for the year ended December 31, 2019[49]. - The employee costs, including directors' remuneration, amounted to approximately SGD 2,322,000 for the year ended December 31, 2019, compared to approximately SGD 1,812,000 for the year ended December 31, 2018[64]. Business Expansion and Strategy - The company expanded its medical aesthetics services by opening a new clinic focused on appearance-related treatments, managed by newly hired dermatologists[29]. - A new clinic was established on Orchard Road to develop a "Family and Skin" concept, operated by three general practitioners[29]. - The company has formed a joint venture agreement with reputable local partners in Hong Kong to establish a comprehensive specialty center focusing on dermatology, aesthetics, preventive and regenerative medicine, and obstetrics[29]. - The group plans to expand its market share in Singapore's dermatology and surgical services industry, targeting growth opportunities in Hong Kong and China[37]. - The company aims to enhance the quality and variety of services at existing clinics and establish new medical beauty clinics as part of its business strategy[37]. Market Outlook - The company anticipates significant demand for high-quality topical skincare products, such as hand sanitizers and hand creams, due to the global outbreak of COVID-19[31]. - The company believes it has laid a solid foundation in 2019 for entering a phase of rapid growth and development in the coming years[29]. - The company is prepared to navigate uncertainties and challenges in 2020, expecting to benefit from pent-up demand once the pandemic is under control[31]. - The company has identified increasing opportunities in the Greater China region, particularly in the Greater Bay Area, for medical tourism[29]. Shareholder Information - The company expressed gratitude to shareholders, customers, and business partners for their continued support[33]. - The company did not recommend the payment of a final dividend for the year ended December 31, 2019[56]. - The distributable reserves available for shareholders as of December 31, 2019, are approximately SGD 5.367 million[95]. - The company has confirmed that at least 25% of its total issued share capital is held by the public[142]. Corporate Governance - The company emphasizes the importance of compliance with regulatory requirements and has not encountered any significant violations during the reporting period[90]. - The company is committed to maintaining high standards of corporate governance and accountability through its board structure and committee oversight[160]. - The board consists of six directors, with three executive directors and three independent non-executive directors[171]. - The company has adopted the corporate governance code as per GEM listing rules and has complied with all applicable provisions for the year ending December 31, 2019[172]. - The company has established appropriate insurance arrangements for directors facing legal actions due to company activities[174]. Risk Management - The company has established a risk management and internal control system to manage operational risks and ensure the effectiveness of financial reporting[197]. - The company’s internal auditor, MS Risk Management Pte. Ltd., confirmed the effectiveness of the internal control and risk management systems without significant deficiencies[198]. - The outbreak of a respiratory disease caused by the novel coronavirus may impact the group's business in the coming year, with management currently assessing the financial implications[144]. Management and Directors - The company has a remuneration committee that reviews the salaries of directors annually based on performance and operational results[158][162]. - The company has established a strategy for independent opinions on governance, performance, and internal controls through its independent non-executive directors[160]. - There are no disclosed connections between the directors and major shareholders or management, ensuring independence in governance[162]. - The company arranged a seminar for directors regarding GEM listing rules and relevant laws, with full attendance by all directors[180].